Eikon Therapeutics is using super-resolution microscopy for drug development. Advances in super-resolution fluorescence microscopy has now made it possible to follow the dynamics of individual proteins in living cells. Measurements from single particle tracking enable the calculation of protein angular movements, on-rates/off-rates and residence times for binding events. Eikon is using this technology to assess protein dynamics and reveal novel biological mechanisms of action, thus providing new therapeutic approaches. This requires the combination of engineering, computation, biology, medicinal chemistry and pharmacology expertise. Eikon’s pipeline is designed to achieve effective therapeutics for unmet medical needs.

<p>Eikon Therapeutics is using super-resolution microscopy for drug development. Advances in super-resolution fluorescence microscopy has now made it possible to follow the dynamics of individual proteins in living cells. Measurements from single particle tracking enable the calculation of protein angular movements, on-rates/off-rates and residence times for binding events. Eikon is using this technology to assess protein dynamics and reveal novel biological mechanisms of action, thus providing new therapeutic approaches. This requires the combination of engineering, computation, biology, medicinal chemistry and pharmacology expertise. Eikon’s pipeline is designed to achieve effective therapeutics for unmet medical needs.</p>


Eikon Therapeutics

Eikon Therapeutics Appoints COO: People in the News: 11/27/24 | Business | Nov 2024 - Photonics.com

Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference - Business Wire

Fierce Next Gen: Eikon drops hints at early pipeline, plans for $660M-plus reservoir - Fierce Biotech

 Manager, Study Start Up job with Eikon Therapeutics | 2886695 

Eikon Therapeutics Management to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire

 Eikon Therapeutics advances preclinical pipeline 

We are pleased to announce that Michael Klobuchar is joining Eikon Therapeutics as our new Chief Operating Officer! Mike joins Eikon from Merck & Co. Inc. where he spent more than 25 years in senior leadership roles across R&D, manufacturing, finance, and corporate strategy, most recently as Executive Vice President & Chief Strategy Officer.

“Mike is an outstanding leader whose deep experience in navigating complex industrial strategies and his proven track record of operational excellence make him the ideal person to lead Eikon’s infrastructure development as we scale our efforts to bring transformative discovery technologies to scientists and innovative new therapies to patients,” said Eikon CEO & Board Chair Roger M. Perlmutter, M.D., Ph.D.

At Eikon, we are dedicated to advancing our pioneering single-molecule tracking (SMT) platform to develop next-generation therapeutics. As we continue to scale and push the boundaries of what’s possible, Mike will play a pivotal role in driving our operational excellence and strategic growth, ensuring that Eikon remains at the forefront of scientific discovery and patient impact.

Learn more here: https://lnkd.in/gxUbJ-KD

Please join us in welcoming Mike to #TeamEikon!

 Senior Staff Optical Engineer job with Eikon Therapeutics | 2923124 

Eikon Therapeutics Expands Operations In New York City - Contract Pharma

Eikon Therapeutics strikes lease deal to shift headquarters from East Bay to Millbrae - Silicon Valley

Eikon Acquires Broad Development Pipeline, Raises $106M in Series C Funding - BioSpace

Eikon Therapeutics gains rights to batch of clinical-stage oncology assets - The Pharma Letter

Eikon Therapeutics Announces the Election of Kenneth C. Frazier to Its Board of Directors - Business Wire

 Electrical Engineering Technician job with Eikon Therapeutics | 2923714 

Log in

Quantum Myriad™ All-Flash File and Object Solution Now Generally Available - PR Newswire

Eikon Therapeutics Takes 25K-SF at Alexandria Center for Life Science - Commercial Observer

Biotech company Eikon Therapeutics to open New York City operations base - The Business Journals

 Service Technician 2 job with Eikon Therapeutics | 2908326 

Eikon snaps up clinical pipeline thanks to 'buyer's market'

Eikon Therapeutics advances preclinical pipeline - BioWorld Online

We’re so proud of #TeamEikon for how they support and give back to our communities! 

Eikon’s Veterans Employee Resource Group (ERG) includes 11 veterans, military spouses, and military supporters. This recent partnership with Operation Homefront is the first of many events planned in the coming months where the group will be volunteering and showing support for our local military community. 


              Bridging the Data Gap: How Eikon Therapeutics is Enhancing Drug Discovery with AI 

            

 Eikon Therapeutics on LinkedIn: #aacr24 #teameikon #cancerresearch #asco24 

 Director, Financial Planning & Analysis (FP&A) - R&D job with Eikon Therapeutics | 2871325 

Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress - Business Wire

Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline - Business Wire

 Here’s One Un-Bearish Indicator: Series B Is Holding Up 

Eikon Therapeutics Announces Long-Term Lease with Alexandria Real Estate Equities, Inc. for New Corporate Headquarters in the San Francisco Bay Area - Business Wire

"I’m excited about the prospect that new technological advances have afforded us to further accelerate innovative therapeutic development.”

Ten years after playing an instrumental role in bringing Keytruda —one of the most impactful cancer therapies in history— to market, Roy Baynes, MD, PhD, now serves as Eikon Therapeutics' Chief Medical Officer. At Eikon, Roy is building one of the industry's most sophisticated clinical organizations and a therapeutic pipeline with the potential to deliver important new medicines to address serious illnesses that reflect areas of unmet medical need.

In a recent podcast interview, Roy shared insights from his accomplished career and discussed what excites him most about the future of medicine, particularly the potential of new technologies and artificial intelligence.

Catch the full interview and explore current opportunities to join Roy's growing clinical team at Eikon (links in comments).

#TeamEikon #Biotech

Eikon snaps up clinical pipeline thanks to 'buyer's market,' while internal pipeline remains covert - Fierce Biotech

 Eikon Therapeutics strikes lease deal to shift headquarters from East Bay to Millbrae 

 Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonists 

 Senior Clinical Data Manager job with Eikon Therapeutics | 2900187 

Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer - BioSpace

 Executive Assistant to the Chief Scientific Officer job with Eikon Therapeutics | 2884542 

 Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer 

 Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targets 

Lilly’s board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon - Endpoints News

Exclusive: Roger Perlmutter on the biggest problem in Big Pharma, leaving Merck, and building Eikon - Endpoints News

Eikon Therapeutics Signs Major Lease at New Millbrae Campus - Connect CRE

Chutes & Ladders—After 9 years at Merck, Roy Baynes follows Roger Perlmutter to Eikon - Fierce Biotech

 Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 

 Whether Remote Or On-Site, Here’s How The Hottest Early-Stage Startups Compare 

24590 Clawiter Road
Hayward, CA 94545

8th DDR Inhibitors Summit 2025 - MetroWest Daily News

Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors - Business Wire

Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team - Business Wire

Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranks - Fierce Biotech

2Q21—a slowing of the pace - Nature.com

Eikon Therapeutics Announces the Election of Robert L. Huffines to its Board of Directors - BioSpace

 Eikon Therapeutics leases Manhattan facility as East Coast base of operations 

'How can you understand life if you don't look at it live?' — Eikon Therapeutics rakes in $518M - TechCrunch

 Read Article 

3929 Point Eden Way
Hayward, CA 94545

Life Sciences Community Advances Toward Next Phase of Innovation at Veeva R&D and Quality Summit - PR Newswire

Eikon cuts staff to 'become more efficient,' CEO Roger ...

 Clinical Trial Associate, Oncology job with Eikon Therapeutics | 2886194 

Chutes & Ladders—Eikon adds more than a dozen new hires to clinical development unit - Fierce Biotech

Eikon Therapeutics Expands Operations in New York City - Contract Pharma

Reuniting the band: Former Merck CEO follows 3 former colleagues to Eikon - Fierce Biotech

This Startup Raised Over $500 Million To Find Better Drugs With Nobel Prize-Winning Microscopes - Forbes

Merck Veteran Roger Perlmutter Emerges From Stealth Mode With Eikon Therapeutics - BioSpace

Eikon cuts staff 'to become more efficient,' letter from CEO Roger Perlmutter reveals - Fierce Biotech

Eikon Therapeutics Builds Leading Clinical Development Organization with Appointment of Senior Team with Extensive Industry Expertise - Business Wire

Topping Out for New Eikon Offices in Millbrae, San Mateo County - San Francisco YIMBY

 Principal Engineer, Data Integration job with Eikon Therapeutics | 2905428 

 Eikon Therapeutics Announces the Election of Robert L. Huffines to its Board of Directors 

WRN inhibition leads to its chromatin-associated degradation via the PIAS4-RNF4-p97/VCP axis - Nature.com

 North American Startup Investment Fell 11% In Q1 In First Quarterly Decline In Nearly 2 Years 

 The Week’s 10 Biggest Funding Rounds: Silicon Ranch Powers Up With $775M, Eikon Scopes Out $517.8M 

Eikon Therapeutics Appoints Alfred Bowie Jr, PhD as Chief Financial Officer - Business Wire

We’re looking forward to the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 4th in New York City. Eikon Therapeutics’ CEO Roger M. Perlmutter and CFO Alfred (Freddie) Bowie will present a business update on the company’s progress including recent advancements in the company’s pipeline and clinical development programs, as well as updates related to our Eikon Systems business.

To access the archived recording after the event, visit the link in comments. 

Eikon Therapeutics Closes $148 Million Series A Financing to Develop High-Throughput, Super-Resolution Microscopy for Drug Discovery - Business Wire

 What Current Series B Trends Say About The US Startup Scene 

Navigating the complexities of clinical trial supply chains is more challenging than ever as the industry adapts to new technologies and ever-changing global regulations.

On September 17, Eikon Therapeutics’ Senior Director of Clinical Supply Chain Reid Tonik will share insights on “Creating a Clinical Supply Chain Playbook for Onboarding Acquired Assets” at Clinical Trial Supply West Coast in San Francisco.

Reid will cover best practices and actionable strategies including:

➡ Identifying priorities and guiding transition activities while mitigating risks to patient dosing and trial continuity in a culturally and personally mindful way.
➡ Deciding when and what to integrate, and assessing the impact on the acquired portfolio.
➡ Tools of the trade and lessons learned from past mistakes.

We hope to see you there!
 
#TeamEikon #ClinicalTrials #ClinicalOperations #CTSWestCoast

 Sourcing/Category Manager job with Eikon Therapeutics | 2922322 

We're excited to see this collaborative work from the Tim Mitchison and Pamela Silver labs at Harvard Medical School posted on biorXiv. 

At Eikon, we’ve seen how measuring the movement of proteins in the cell can be a powerful and versatile tool for drug discovery. By participating in Eikon's Technology Access Program, Rui Tong Quek was able to measure protein-protein interactions with our single-molecule tracking (SMT) platform in support of her research on condensate formation.

Eikon’s SMT platform permits us to assay protein motion in live cells by measuring the movement of millions of individual proteins. Using Eikon’s high-throughput platform, Rui measured the condensate formation of nucleocapsid (N) protein from SARS-CoV-2. Not only could she measure changes in N-protein motion upon GSK3 inhibition, but she could also see those changes starting to occur within an hour, well before any sort of condensates become visible.

Check out the preprint or learn more: https://lnkd.in/gJupmUys

#DrugDiscovery #SingleMoleculeTracking #SMT 

Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire

 Eikon Therapeutics welcomes Robbie Huffines to its Board as Independent Director 

 Associate Director, Data Management job with Eikon Therapeutics | 2887780 

Eikon Therapeutics Announces Lease for East Coast Base of Operations in New York City - Business Wire

 Eikon Clinical Community job with Eikon Therapeutics | 2926206 

Startup Eikon, led by Merck vets, buys drugs from three biotechs and banks another $106M - BioPharma Dive

At Eikon Therapeutics, our Clinical team plays a vital role in translating groundbreaking discoveries into life-changing medicines for patients with unmet needs, including cancer and neurodegenerative diseases.

With a commitment to patient-centered clinical excellence, we prioritize the well-being of participants in our clinical trials and strive to deliver high-quality data that supports the development of effective therapies. Our track record showcases our integrated capabilities to advance both in-licensed assets and those emerging from our proprietary platform.

As part of #TeamEikon, you'll contribute to a vision that redefines the boundaries of science, driving innovation that has the potential to transform the lives of patients around the world.

Explore West- and East-Coast opportunities to join our clinical team here: https://lnkd.in/g7V6b9RZ

#ClinicalResearch #HealthcareInnovation #ScienceCareers

Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer - Business Wire

 Biotech Startup Funding Has Also Slowed In 2022 

 Ex-Merck R&D chief Perlmutter takes reins at drug discovery startup Eikon 

 Stealthy Eikon unveils $148M in funding and ex-Merck exec Perlmutter at helm 

Alexandria Leases 285K SF To Eikon Therapeutics At New Millbrae Campus - The Real Deal

 Manager, Study Start Up job with Eikon Therapeutics | 2921940 

 How Eikon Uses Fluorescence Microscopy for Drug Discovery 

Hyundai, Eikon Therapeutics, Bank of Montreal and Arco Design all sign leases at Class A office tower in Jersey City - ROI-NJ.com

Pfizer and Eikon Expand East Coast Presence with New York Facilities - BioSpace

We’re excited to announce the launch of our new website!

The redesigned site reflects our progress toward advancing breakthrough therapeutics through the purposeful integration of science and engineering. With the power of live-cell imaging, proprietary technologies, and data science, Eikon’s interdisciplinary team is uncovering new drug candidates and accelerating the path from research to treatment so we can deliver new medicines that address serious illnesses.

What you’ll find:

➡️ Insights into our proprietary technologies including our pioneering single-molecule tracking (SMT) platform
➡️Published papers and resources on our novel research
➡️Opportunities to join our growing team with East and West Coast openings

We invite you to explore and connect with us as we push the boundaries of science. Visit us at: www.eikontx.com.

#DrugDiscovery #Biotech #Therapeutics #TeamEikon

C&W: Biopharma firm, automaker among newest tenants at Jersey City office tower - Real Estate NJ

Eikon Boasts Stellar Leadership Lineup and Massive $518 Million Series B - BioSpace

 Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranks 

Chutes & Ladders—Eikon adds more than a dozen new ...

We're looking forward to next week's Goldman Sachs Global Healthcare Conference, where our CEO, Roger M. Perlmutter, and CFO, Alfred (Freddie) Bowie, will be providing important business updates and highlighting the exciting progress of our lead clinical programs, along with key data presented at the recent #AACR24 and #ASCO24 meetings.

To learn more and access an archived recording of the presentation, please visit: www.EikonTx.com/news.

#TeamEikon #Biotech

Eikon Therapeutics

Business:

Drug notes:

About: